Covid 19 Vaccine race:Close or Far
Covid 19 Vaccine
Half of this is year is going to be over now,no one would have thought that we will be facing such devastation just because of an invisible enemy called Covid 19. As per current figure by WHO, the total number of confirmed cases hovering around 8 million out of which 4 million have already died. But the numbers are not going down soon as researchers are still studying and virus is mutating frequently. So at this moment it is imperative that people follow social distancing norms and government guidelines. Scientists all over the world are busy finding vaccine to curb this pandemic. So far as Covid 19 Vaccine research is concerned, developed countries should take the lead as they have required medical advancement to take these researches to its logical conclusion, also because they are among the most affected.
At present more than 100 vaccines are under phase II trial and countries like France, Britain, US, Germany and Nether-land have already placed orders for millions of Vaccine. Few of the front runners in this race for vaccine are Imperial college London, Moderna Inc from US, Cure Vac of Germany and Oxford AstraZeneca of UK. The Imperial college has already tested its vaccine on animals and probably this week they will start immunizing 300 volunteers and in next phase they will immunize 6000 people in October. If everything goes fine Britain hopes to have this vaccine for its citizens by end of this year. Moderna of US is also going for final trial in next month with 30000 people and Vaccine might come by November. Similarly Oxford AstaZeneca will end its Phase I trial soon and start phase III trials on humans, they expect to get results of the clinical trials by September and hoping to deliver Covid 19 Vaccine by October. They have already signed a deal of 400 Covid 19 Vaccine for US and 100 Vaccine for UK if human trial goes successful.Though Robin Shattock of Imperial college has cautioned that early vaccines may come with some limitations. For more detail Click here.